275 related articles for article (PubMed ID: 30688675)
21. Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.
Fan J; Dai X; Wang Z; Huang B; Shi H; Luo D; Zhang J; Cai W; Nie X; Hirsch FR
Clin Lung Cancer; 2019 Jul; 20(4):e517-e530. PubMed ID: 31138506
[TBL] [Abstract][Full Text] [Related]
22. EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India.
Tarigopula A; Ramasubban G; Chandrashekar V; Govindasami P; Chandran C
Cancer Rep (Hoboken); 2020 Dec; 3(6):e1288. PubMed ID: 32881404
[TBL] [Abstract][Full Text] [Related]
23. Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.
Mendoza DP; Stowell J; Muzikansky A; Shepard JO; Shaw AT; Digumarthy SR
Clin Lung Cancer; 2019 Sep; 20(5):339-349. PubMed ID: 31164317
[TBL] [Abstract][Full Text] [Related]
24. Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.
Nakamura M; Kageyama SI; Niho S; Okumura M; Hojo H; Motegi A; Nakamura N; Zenda S; Yoh K; Goto K; Akimoto T
Clin Lung Cancer; 2019 May; 20(3):e256-e264. PubMed ID: 30926356
[TBL] [Abstract][Full Text] [Related]
25. Application of Ventana immunocytochemical analysis on ThinPrep cytology slides for detection of ALK rearrangement in patients with advanced non-small-cell lung cancer.
Guo HQ; Jia J; Zhao LL; Zhao H; Wang C; Sun Y; Ying JM; Guo L; Cao J; Zhang ZH
BMC Cancer; 2018 Dec; 18(1):1277. PubMed ID: 30572846
[TBL] [Abstract][Full Text] [Related]
26. Investigation of EGFR and ALK mutation frequency and treatment results in advanced non-small cell lung cancer.
Komurcuoglu B; Karakurt G; Kaya OO; Diniz G; Kırbıyık O; Evkan A; Yalnız E
J Cancer Res Ther; 2023 Apr; 19(Supplement):S183-S190. PubMed ID: 37147996
[TBL] [Abstract][Full Text] [Related]
27. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
[TBL] [Abstract][Full Text] [Related]
28. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
[TBL] [Abstract][Full Text] [Related]
29. Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.
DeMaio A; Clarke JM; Dash R; Sebastian S; Wahidi MM; Shofer SL; Cheng GZ; Li X; Wang X; Mahmood K
J Bronchology Interv Pulmonol; 2019 Apr; 26(2):96-101. PubMed ID: 30048416
[TBL] [Abstract][Full Text] [Related]
30. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
[TBL] [Abstract][Full Text] [Related]
31. [National variation in molecular diagnostics in metastatic lung cancer].
Kuijpers CCHJ; van den Heuvel MM; Overbeek LIH; van Slooten HJ; van Lindert ASR; Damhuis RAM; Willems SM
Ned Tijdschr Geneeskd; 2018 Dec; 162():. PubMed ID: 30570921
[TBL] [Abstract][Full Text] [Related]
32. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
[TBL] [Abstract][Full Text] [Related]
33. SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy.
Ji X; Liu Y; Mei F; Li X; Zhang M; Yao B; Wu R; You J; Pei F
Sci Rep; 2021 Jul; 11(1):14031. PubMed ID: 34234236
[TBL] [Abstract][Full Text] [Related]
34. Predictive markers in lung cancer: a few hints for the practicing pathologist.
Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
[TBL] [Abstract][Full Text] [Related]
35. EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder.
Alexander RE; Montironi R; Lopez-Beltran A; Williamson SR; Wang M; Post KM; Sen JD; Arnold AK; Zhang S; Wang X; Koch MO; Hahn NM; Masterson TA; MacLennan GT; Davidson DD; Compérat E; Cheng L
Mod Pathol; 2014 Jan; 27(1):107-12. PubMed ID: 23887300
[TBL] [Abstract][Full Text] [Related]
36. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
37. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
Bozzetti C; Nizzoli R; Tiseo M; Squadrilli A; Lagrasta C; Buti S; Gasparro D; Zanoni D; Majori M; De Filippo M; Mazzoni F; Maddau C; Naldi N; Sammarelli G; Frati C; Pinto C; Ardizzoni A
Diagn Cytopathol; 2015 Nov; 43(11):941-6. PubMed ID: 26152804
[TBL] [Abstract][Full Text] [Related]
38. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
39. [Identification of an optimal algorithm for effective diagnostics of non-small cell lung cancer with ALK gene rearrangement - implementation of the method and practical experiences with routine diagnostics].
Rozkoš T; Ryška A; Nová M; Hornychová H; Krbal L; Matěj R; Laco J
Cesk Patol; 2017; 53(2):89-96. PubMed ID: 28597670
[TBL] [Abstract][Full Text] [Related]
40. ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA.
Bravaccini S; Tumedei MM; Ulivi P; Zoli W; Calistri D; Candoli P; Amadori D; Puccetti M
Cytopathology; 2016 Apr; 27(2):103-7. PubMed ID: 25757141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
